These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23110259)

  • 1. Axitinib, a new therapeutic option in renal cell carcinoma.
    Kessler ER; Bowles DW; Flaig TW; Lam ET; Jimeno A
    Drugs Today (Barc); 2012 Oct; 48(10):633-44. PubMed ID: 23110259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
    Goldstein R; Pickering L; Larkin J
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axitinib for the treatment of metastatic renal cell carcinoma.
    Parekh H; Griswold J; Rini B
    Future Oncol; 2016 Feb; 12(3):303-11. PubMed ID: 26769075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
    Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T
    Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
    Carmichael C; Lau C; Josephson DY; Pal SK
    Clin Adv Hematol Oncol; 2012 May; 10(5):307-14. PubMed ID: 22706540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
    Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
    Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib in the treatment of metastatic renal cell carcinoma.
    Ho TH; Jonasch E
    Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
    Thiery-Vuillemin A; Orillard E; Mouillet G; Calcagno F; Devillard N; Bouchet S; Royer B
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1273-1276. PubMed ID: 28451830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib in metastatic renal cell carcinoma.
    Albiges L; Gizzi M; Carton E; Escudier B
    Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
    Zakharia Y; Zakharia K; Rixe O
    Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
    Rini BI; Melichar B; Fishman MN; Oya M; Pithavala YK; Chen Y; Bair AH; Grünwald V
    Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC.
    Payton S
    Nat Rev Urol; 2013 Jun; 10(6):308. PubMed ID: 23649292
    [No Abstract]   [Full Text] [Related]  

  • 14. Axitinib-induced acute pancreatitis: a case report.
    Péron J; Khenifer S; Potier V; Vitry T; Pasquet F; Rassat R; Pavic M
    Anticancer Drugs; 2014 Apr; 25(4):478-9. PubMed ID: 24398664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
    Umeyama Y; Shibasaki Y; Akaza H
    Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney cancer: progress and controversies in neoadjuvant therapy.
    Posadas EM; Figlin RA
    Nat Rev Urol; 2014 May; 11(5):254-5. PubMed ID: 24752207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SU11248 and AG013736: current data and future trials in renal cell carcinoma.
    Rini BI
    Clin Genitourin Cancer; 2005 Dec; 4(3):175-80. PubMed ID: 16425985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib (Inlyta) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jun; 54(1392):47-8. PubMed ID: 22683928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.